@article{oai:repo.qst.go.jp:00079681,
 author = {崔, 星 and 山田, 泰寿 and 平川, 博一 and 鈴木, 雅雄 and 藤森, 亮 and Sai, Sei and Yamada, Taiju and Hirakawa, Hirokazu and Suzuki, Masao and Fujimori, Akira},
 journal = {平成30年度放射線医学総合研究所重粒子線がん治療装置等共同利用研究報告書},
 month = {Apr},
 note = {Pancreatic ductal adenocarcinoma, which constitutes >90% of pancreatic cancers (PC) in humans, is one of the most devastating human malignancies. Despite extensive research during the past decades, the dismal prognosis has not markedly improved and is almost uniformly lethal, with an average overall 5-year survival of <5%. In this study we examined how effective on control PC xenograft tumor by carbon ion beam alone or in combination with TS-1, an oral anti-cancer agent, in vivo. We found that PANC1 xenograft tumor growth is slow (8 weeks after injection of the cells the tumors reach around 10 mm), whereas PK45 xenograft tumor growth is relatively fast (4 weeks after injection of the cells the tumors reach around 10 mm). Thus we used PK45 xenograft in this study. Carbon ion beam irradiation with 25Gy effectively suppressed PK45 xenograft tumor volume and in combination with TS-1 (10.0mg/kg po) significantly enhanced its action. Carbon ion beam alone with high dose (35Gy) significantly reduced tumor volume but TS-1 alone did not. Histopathological analysis showed that carbon ion beam with 25 Gy remarkably induced tumor cell fibrosis, cavitation and necrosis compared with that of by 30 Gy of X-ray irradiation or TS-1 alone. The immunohistochemical analysis of combination treatment of carbon ion beam and TS-1 is undergoing. In conclusion, high dose of carbon ion beams or relatively low dose of carbon ion beam combined with TS-1 has superior potential to control PC xenograft tumor.},
 pages = {40--44},
 title = {移植腫瘍モデルを用いた重粒子線治療適応拡大のための基礎研究},
 year = {2019}
}